X0508 4 2024-03-31 0001645469 Monopar Therapeutics MNPR 0001727334 Robinson Chandler 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 1 1 Chief Executive Officer 0 Common Stock 2024-03-31 4 M 0 24474 A 173302.80 D Common Stock 2024-03-31 4 F 0 7172 0.681 D 166130.80 D Common Stock 4111272.88 I See Footnote Common Stock 166667 I See Footnote Restricted Stock Units 2024-03-31 4 M 0 24474 0 D Common Stock 24474 197811 D Represents shares acquired on vesting and settlement of restricted stock units. Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. This is based upon the 4,111,272.88 shares of Monopar common stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Dr. Robinson disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. This is based upon the 166,667 shares of Monopar common stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 166,667 shares. Dr. Robinson disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein. On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. /s/ Kim R Tsuchimoto, Attorney-in-fact 2024-04-02